| The impacts of government reimbursement negotiation on targeted anticancer medication price, volume and spending in China Y Zhang, H Wushouer, S Han, M Fu, X Guan, L Shi, A Wagner BMJ Global Health 6 (7), e006196, 2021 | 37 | 2021 |
| Overall survival benefits of cancer drugs approved in China from 2005 to 2020 Y Zhang, H Naci, AK Wagner, Z Xu, Y Yang, J Zhu, J Ji, L Shi, X Guan JAMA network open 5 (8), e2225973-e2225973, 2022 | 23 | 2022 |
| Prices and clinical benefit of national price-negotiated anticancer medicines in China Y Zhang, Y Wei, H Li, Y Chen, Y Guo, S Han, L Shi, X Guan Pharmacoeconomics 40 (7), 715-724, 2022 | 22 | 2022 |
| Differences in reimbursement listing of anticancer therapies in China: an observational study X Guan, Y Zhang, H Wushouer, L Shi, D Ross-Degnan, AK Wagner BMJ open 10 (1), e031203, 2020 | 17 | 2020 |
| Newly approved cancer drugs in China—innovation and clinical benefit Y Zhang, AK Wagner, X Guan Nature Reviews Clinical Oncology 20 (3), 135-136, 2023 | 8 | 2023 |
| Physician patient-sharing relationships and healthcare costs and utilization in China: social network analysis based on health insurance data H Hu, Y Zhang, D Zhu, X Guan, L Shi Postgraduate Medicine 133 (7), 798-806, 2021 | 6 | 2021 |
| The impact of government reimbursement negotiation on targeted anticancer medicines use and cost in China: A cohort study based on national health insurance data Y Yang, Y Zhang, AK Wagner, H Li, L Shi, X Guan Journal of Global Health 13, 2023 | 1 | 2023 |
| Childhood cancer drugs in China: An overview and comparison of regulatory approvals in China and the United States Y Zhang, A Katharina Wagner, H Du, T Han, S Gupta, AE Denburg, ... International Journal of Cancer 150 (3), 482-490, 2022 | 1 | 2022 |
| Misleading reporting in statistically not significant oncology trials—joining efforts toward unbiased results interpretation Y Zhang, X Guan JAMA Network Open 4 (12), e2138695-e2138695, 2021 | 1 | 2021 |
| The impact of the provincial reimbursement scheme on the use of targeted anticancer medications in Zhejiang, China: a controlled interrupted time-series analysis. C Huang, C Oi Lam Ung, H Wushouer, Z Xu, Y Zhang, X Guan, L Shi Journal of Chinese Pharmaceutical Sciences 30 (7), 2021 | 1 | 2021 |
| Improvements in the health-related quality-of-life benefit of cancer drugs approved in China, 2005–2020: an observational study L Zhang, Y Zhang, H Li, L Shi, X Guan The Lancet Regional Health–Western Pacific 46, 2024 | | 2024 |
| Prevalence of aggressive care among patients with cancer near the end of life: a systematic review and meta-analysis Z Ma, H Li, Y Zhang, L Zhang, G Huang, Y Zhang, L Shi, W Liu, Z An, ... EClinicalMedicine 71, 2024 | | 2024 |
| Cancer drug indication approvals in China and the United States: a comparison of approval times and clinical benefit, 2001–2020 Y Wei, Y Zhang, Z Xu, G Wang, Y Zhou, H Li, L Shi, H Naci, AK Wagner, ... The Lancet Regional Health–Western Pacific 45, 2024 | | 2024 |
| Use of suboptimal control arms in randomized clinical trials of investigational cancer drugs in China, 2016–2021: An observational study Y Zhang, D Chen, S Cheng, Z Liang, L Yang, Q Li, L Bai, H Li, W Liu, ... PLoS medicine 20 (12), e1004319, 2023 | | 2023 |
| Health status of middle-aged and elderly cancer survivors in China. H Du, Q Bao, H Li, Y Zhang, H Wushouer, L Shi, X Guan Journal of Chinese Pharmaceutical Sciences 32 (9), 2023 | | 2023 |
| Evidence of clinical benefit of WHO essential anticancer medicines for children, 2011–2021 L Bai, Y Zhan, Y Zhou, Y Zhang, L Shi, S Gupta, A Denburg, X Guan Eclinicalmedicine 59, 2023 | | 2023 |
Xiaodong GuanPeking UniversityVerified email at pku.edu.cn
